Replimune is a high-stakes biotech catalyst play where RP1 approval could transform the equity story, but another FDA rejection could severely impair shareholder value.
Overview
Replimune is a pre-revenue clinical-stage biotech developing next-generation oncolytic immunotherapies for advanced solid tumors. Its lead asset, RP1, targets post-PD-1 advanced melanoma with an outpatient, off-the-shelf intratumoral therapy designed to combine direct tumor killing with systemic immune activation. The company’s opportunity is meaningful because many melanoma patients fail checkpoint inhibitors and current alternatives such as TIL therapy are complex and toxic. However, the thesis is highly binary: RP1 approval could unlock commercialization, while another FDA rejection could force severe dilution or insolvency.